Review
Immunology
Chunyan Shi, Yan Wang, Jianxin Xue, Xiaojuan Zhou
Summary: ICIs are effective in NSCLC patients regardless of PD-L1 expression, and combination with chemotherapy can improve efficacy. Patients with rare mutations show better response to ICIs in terms of progression-free survival.
FRONTIERS IN IMMUNOLOGY
(2022)
Review
Medicine, General & Internal
Chu-Ling Li, Yong Song
Summary: Immunotherapy has greatly impacted the treatment of non-small cell lung cancer, with combination strategies showing promising clinical outcomes. However, there is still room for improvement in response rates, necessitating exploration of alternative combination models and candidate selection strategies.
CHINESE MEDICAL JOURNAL
(2021)
Article
Oncology
Liying Yang, Wei Zhang, Jujie Sun, Guanqun Yang, Siqi Cai, Fenghao Sun, Ligang Xing, Xiaorong Sun
Summary: This study investigated the relationship between the spatial interaction of PD-L1-positive tumor cells and T cells with specific functions and the recurrence of NSCLC, and optimized prognostic stratification. It was found that the number of PD-L1-positive tumor cells was higher in the tumor center compared to the invasion margin, while the number of T cells, especially PD-1-positive CD8 T cells, was lower. The proximity between CD8 T cells and PD-L1-positive tumor cells was closer, especially for exhausted CD8 T cells. The density and percentage of PD-1-positive CD4 T cells interacting with PD-L1-positive tumor cells were associated with recurrence, with increasing risk. Patients with low PD-1-positive CD4 count and high PD-1-positive CD4 density had a significantly higher risk of recurrence. The spatial proximity assessment of PD-1/PD-L1 contributes to a better understanding of tumor immune escape and provides prognostic information for NSCLC patients.
CANCER IMMUNOLOGY IMMUNOTHERAPY
(2023)
Article
Oncology
Qiang Zheng, Yan Huang, Xin Zeng, Xiaoyan Chen, Shihong Shao, Yan Jin, Qianqian Xue, Yue Wang, Yan Guo, Bin Gu, Chunyan Wu, Yuan Li
Summary: The study evaluated the clinicopathological and molecular profiles associated with PD-L1 expression in NSCLC in a large, multi-center Chinese cohort. PD-L1 expression was linked to histological type, pathological features, and driver mutation status, highlighting implications for clinical practice.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
(2021)
Article
Oncology
Qiang Wen, Zhe Yang, Honghai Dai, Alei Feng, Qiang Li
Summary: In patients with advanced-stage lung cancer, radiomics features extracted from pretreatment CT images were found to effectively predict PD-L1 expression level and TMB status. Predictive models combining radiomics features with clinical and morphological factors significantly improved the predictive efficacy and provided valuable guidance for immunotherapy in clinical practice.
FRONTIERS IN ONCOLOGY
(2021)
Article
Immunology
David G. Coffey, Yuexin Xu, Andrea M. H. Towlerton, Marcin Kowanetz, Priti Hegde, Martine Darwish, Mahesh Yadav, Craig Blanchette, Shannon M. Ruppert, Sarah Bertino, Qikai Xu, Andrew Ferretti, Adam Weinheimer, Matthew Hellmann, Angel Qin, Dafydd Thomas, Edus H. Warren, Nithya Ramnath
Summary: This article reports the clinical history of an exceptional responder with metastatic non-small cell lung cancer who achieved a complete and enduring remission after treatment with radiation and atezolizumab, an anti-programmed death-ligand 1 (PD-L1) monoclonal antibody. The study reveals oligoclonal T cell expansion and tumor reactivity in the patient, suggesting that the exceptional response may be attributed to increased tumor immunogenicity promoted by radiation therapy and the persistence of expanded T cell clones.
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Oncology
Yunfei Shi, Youming Lei, Li Liu, Shiyue Zhang, Wenjing Wang, Juan Zhao, Songhui Zhao, Xiaowei Dong, Ming Yao, Kai Wang, Qing Zhou
Summary: This study aimed to explore novel biomarkers for immune checkpoint inhibitor responses in non-small cell lung cancer (NSCLC) by integrating genomic profiling, tumor mutational burden (TMB), and PD-L1 expression. The study identified that tumors with different alterations in actionable target genes had variable expression of PD-L1 and TMB in NSCLC, and suggested that TP53/KMT2C co-mutation might serve as a predictive biomarker for ICI responses in NSCLC.
Article
Oncology
Kenji Nakahama, Motohiro Izumi, Naoki Yoshimoto, Mitsuru Fukui, Akira Sugimoto, Hiroaki Nagamine, Koichi Ogawa, Kenji Sawa, Yoko Tani, Hiroyasu Kaneda, Shigeki Mitsuoka, Tetsuya Watanabe, Kazuhisa Asai, Tomoya Kawaguchi
Summary: Vimentin expression in NSCLC is associated with immune-checkpoint inhibitor efficacy. Measurement of vimentin expression can help determine appropriate immunotherapy strategies.
Review
Oncology
Peixin Chen, Yunhuan Liu, Yaokai Wen, Caicun Zhou
Summary: Lung cancer is a primary cancer type with high incidence and mortality in China. Risk factors include tobacco use, family history, radiation exposure, and chronic lung diseases. Nationwide screening programs have been effective in increasing early detection and survival rates. Understanding molecular carcinogenesis and identifying oncogenic drivers have facilitated the development of targeted therapy, improving survival for patients with positive drivers.
CANCER COMMUNICATIONS
(2022)
Article
Multidisciplinary Sciences
Will Paces, Elliott Ergon, Elizabeth Bueche, G. Dave Young, Vitria Adisetiyo, Cris Luengo, Meredith James, Charles Caldwell, Dannah Miller, Morgan Wambaugh, Geoffrey Metcalf, Roberto Gianani
Summary: PD-L1 (22C3) digital assay can assist in clinical treatment decisions for non-small cell lung cancer (NSCLC) patients, while reducing the complexity and variability among pathologists.
SCIENTIFIC REPORTS
(2022)
Article
Oncology
Qi Xiong, Boyu Qin, Lingli Xin, Bo Yang, Qi Song, Yu Wang, Sujie Zhang, Yi Hu
Summary: This study investigated the efficacy and safety of anlotinib with or without immunotherapy in NSCLC patients, finding that the combination therapy may have slightly longer PFS than anlotinib alone, but the difference was not statistically significant. Brain metastasis was identified as an independent predictor of PFS in NSCLC patients receiving anlotinib treatment.
FRONTIERS IN ONCOLOGY
(2021)
Article
Oncology
Elizabeth Dudnik, Samuel Kareff, Mor Moskovitz, Chul Kim, Stephen Liu, Anastasiya Lobachov, Teodor Gottfried, Damien Urban, Alona Zer, Ofer Rotem, Amir Onn, Mira Wollner, Jair Bar
Summary: This study of 125 patients suggests a positive impact of ICI on overall survival in aLCNEC, despite the limitations of retrospective design and small sample size.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2021)
Article
Chemistry, Multidisciplinary
Hamadi Madhi, Jeon-Soo Lee, Young Eun Choi, Yan Li, Myoung Hee Kim, Yongdoo Choi, Sung-Ho Goh
Summary: The focus of this study is FOXM1, which is identified as a potential therapeutic target for cancer immunotherapy and associated with the modulation of PD-L1 expression. The study found that selective knockdown of FOXM1 or treatment with TST significantly reduces PD-L1 expression in NSCLC cells and inhibits proliferation. Animal studies showed that TST treatment downregulates PD-L1 expression in NSCLC tumors and reduces tumor size without side effects. Combined treatment with TST and anti-4-1BB antibody induces synergistic therapeutic outcomes against immune resistant lung tumors and increases the number of CD3(+) T cells in tumor tissues.
Article
Oncology
Tiantian Ma, Jin Jiao, Ran Huo, Xiaofang Li, Guotao Fang, Qi Zhao, Weiwei Liu, Xiao Han, Chenglin Xi, Yanan Wang, Yanhong Shang
Summary: PD-1/PD-L1 inhibitors appear to be less effective in NSCLC patients with EGFR mutations. However, some rare EGFR mutation subtypes may benefit from this therapy. PD-L1 expression, TMB, and immune cell infiltration are biomarkers for predicting the efficacy of PD-1/PD-L1 inhibitors in NSCLC patients.
FRONTIERS IN ONCOLOGY
(2022)
Review
Medicine, General & Internal
Ying Cheng, Hui Li, Liang Zhang, Jing-Jing Liu, Chang-Liang Yang, Shuang Zhang
Summary: In recent years, immune checkpoint inhibitors have made significant breakthroughs in the treatment of lung cancer, with combination immunotherapy being widely used to improve efficacy. The combination of PD-1/PD-L1 inhibitors with other treatment modalities is a current research focus.
CHINESE MEDICAL JOURNAL
(2021)
Article
Oncology
Hye Sook Kim, Ji-Youn Han, Dong Hoon Shin, Kun Young Lim, Geon Kook Lee, Jin Young Kim, Wolfgang Jacob, M. Ceppi, Martin Weisser, I James
Article
Oncology
Hye Sook Kim, Kun Young Lim, Soo-Hyun Lee, Hyae Young Kim, Youngjoo Lee, Ji-Youn Han
Summary: This study analyzed treatment failure patterns and subsequent treatment strategies in NSCLC patients treated with osimertinib. The results showed that disease progression during osimertinib treatment commonly occurred in the thorax and pre-existing metastatic sites. Thoracic metastasis was more frequent than bone or brain metastasis. These findings support the intracranial efficacy of osimertinib and can guide treatment strategies for NSCLC patients with EGFR mutations and brain metastasis.